Multiple endocrine neoplasia type 1 medical therapy

Revision as of 15:19, 9 October 2017 by Ajay Gade (talk | contribs)
Jump to navigation Jump to search

Multiple endocrine neoplasia type 1 Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple endocrine neoplasia type 1 from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Multiple endocrine neoplasia type 1 medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multiple endocrine neoplasia type 1 medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multiple endocrine neoplasia type 1 medical therapy

CDC on Multiple endocrine neoplasia type 1 medical therapy

Multiple endocrine neoplasia type 1 medical therapy in the news

Blogs on Multiple endocrine neoplasia type 1 medical therapy

Directions to Hospitals Treating Multiple endocrine neoplasia type 1

Risk calculators and risk factors for Multiple endocrine neoplasia type 1 medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [3]

Overview

Pharmacologic medical therapies for multiple endocrine neoplasia type 1 include cabergoline, somatostatin analogues, and H2- receptor blockers.

Medical Therapy

References

  1. Moyes VJ, Monson JP, Chew SL, Akker SA (2010). "Clinical Use of Cinacalcet in MEN1 Hyperparathyroidism". Int J Endocrinol. 2010: 906163. doi:10.1155/2010/906163. PMC 2877200. PMID 20585352.
  2. [1] Multiple Endocrine Neoplasia Type 1
  3. Sheppard BC, Norton JA, Doppman JL, Maton PN, Gardner JD, Jensen RT (1989). "Management of islet cell tumors in patients with multiple endocrine neoplasia: a prospective study". Surgery. 106 (6): 1108–17, discussion 1117–8. PMID 2573957.
  4. Metz DC, Strader DB, Orbuch M, Koviack PD, Feigenbaum KM, Jensen RT (1993). "Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety". Aliment. Pharmacol. Ther. 7 (6): 597–610. PMID 8161665.
  5. Sadowski SM, Triponez F (2015). "Management of pancreatic neuroendocrine tumors in patients with MEN 1". Gland Surg. 4 (1): 63–8. doi:10.3978/j.issn.2227-684X.2014.12.01. PMC 4321051. PMID 25713781.
  6. Demeure MJ, Klonoff DC, Karam JH, Duh QY, Clark OH (1991). "Insulinomas associated with multiple endocrine neoplasia type I: the need for a different surgical approach". Surgery. 110 (6): 998–1004, discussion 1004–5. PMID 1684067.

Template:WS Template:WH